| 28.05 0.85 (3.13%) | 09-14 15:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.17  |
1-year : | 36.16 |
| Resists | First : | 29.26 |
Second : | 30.95 |
| Pivot price | 27.95 | |||
| Supports | First : | 26.51 | Second : | 22.05 |
| MAs | MA(5) : | 27.63 |
MA(20) : | 28.29 |
| MA(100) : | 25.24 |
MA(250) : | 18.86 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.1 |
D(3) : | 29.9 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 31.43 | Low : | 12.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GHRS ] has closed below upper band by 34.3%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.15 - 28.35 | 28.35 - 28.5 |
| Low: | 26.45 - 26.72 | 26.72 - 26.92 |
| Close: | 26.84 - 27.19 | 27.19 - 27.46 |
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Fri, 11 Sep 2026
GH Research PLC (NASDAQ: GHRS) Files September 2026 Report Under 1934 Exchange Act - Kalkine Media
Fri, 11 Sep 2026
GH Research PLC (GHRS) Stock Price Quote Today & Current Price Chart - Capital.com
Fri, 11 Sep 2026
GH Research (GHRS) plans one-on-one talks at 2026 Morgan Stanley healthcare event - Stock Titan
Fri, 11 Sep 2026
Price-Driven Insight from (GHRS) for Rule-Based Strategy - Stock Traders Daily
Wed, 09 Sep 2026
GH Research (GHRS) director gets 2,303 options not exercisable until 2028 - Stock Titan
Wed, 19 Aug 2026
GH Research Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 24.2 (%) |
| Held by Institutions | 75.3 (%) |
| Shares Short | 3,140 (K) |
| Shares Short P.Month | 1,950 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -18.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -28.62 |
| PEG Ratio | 0 |
| Price to Book value | 5.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -37.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|